AbbVie

AbbVie

Pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues45.8b56.2b58.1b54.3b55.7b58.6b62.7b
% growth38 %23 %3 %(6 %)3 %5 %7 %
EBITDA6.9b16.4b19.7b18.1b25.8b28.5b31.3b
% EBITDA margin15 %29 %34 %33 %46 %49 %50 %
Profit4.6b11.5b11.8b4.9b8.8b11.5b14.1b
% profit margin10 %21 %20 %9 %16 %20 %23 %
EV / revenue5.8x5.5x5.8x5.9x7.2x6.7x6.1x
EV / EBITDA38.4x18.7x17.3x17.7x15.6x13.8x12.3x
R&D budget6.6b7.1b6.5b7.7b---
R&D % of revenue14 %13 %11 %14 %---

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

IPO
Total Funding-

Recent News about AbbVie

Edit
More about AbbVieinfo icon
Edit

AbbVie Inc. is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines. The company operates in the healthcare sector, primarily targeting patients with serious health conditions. AbbVie's portfolio includes treatments for a wide range of diseases, including immunology, oncology, virology, and neuroscience. The company also has a significant presence in the aesthetics market, offering products for aesthetic treatments.

AbbVie's clients include healthcare providers, hospitals, and clinics, as well as patients who require specialized medications. The company operates in various markets around the world, with a strong presence in North America, Europe, and Latin America.

The business model of AbbVie revolves around extensive research and development (R&D) to create new and effective treatments. The company invests heavily in R&D, with a reported $50 billion investment to date, to ensure a steady pipeline of new products. AbbVie makes money by selling its pharmaceutical products to healthcare providers and directly to patients through prescriptions. Additionally, the company generates revenue from its aesthetic products, which are sold to dermatologists and plastic surgeons.

AbbVie's commitment to improving patient care is evident through its continuous efforts in R&D and its focus on addressing unmet medical needs. The company also emphasizes sustainability and responsibility, aiming for science-based targets to ensure long-term growth.

In summary, AbbVie is a leading biopharmaceutical company dedicated to developing innovative treatments for serious health conditions, serving healthcare providers and patients globally, and generating revenue through the sale of its pharmaceutical and aesthetic products.

Keywords: Biopharmaceutical, Immunology, Oncology, Virology, Neuroscience, Aesthetics, Healthcare, R&D, Patient Care, Sustainability.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
  • Edit
Pharmacyclics
ACQUISITION by AbbVie Mar 2015
ImmunoGen
ACQUISITION by AbbVie Nov 2023
Allergan
ACQUISITION by AbbVie Jun 2019
ImmuVen
ACQUISITION by AbbVie Jan 2014
Stemcentrx
ACQUISITION by AbbVie Apr 2016
Syndesi Therapeutics
ACQUISITION by AbbVie Mar 2022
Celsius Therapeutics
ACQUISITION by AbbVie Jun 2024
Exicure
exited
View 52 more